RHJA
NBIX icon

Rice Hall James & Associates’s Neurocrine Biosciences NBIX Stock Holding History

Rice Hall James & Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9M Buy
100,195
+205
+0.2% +$30.4K 0.82% 39
2026
Q1 		$13.2M Buy
99,990
+1,970
+2% +$261K 0.73% 45
2025
Q4 		$13.9M Sell
98,020
-1,445
-1% -$209K 0.77% 43
2025
Q3 		$14M Sell
99,465
-8,917
-8% -$1.21M 0.76% 42
2025
Q2 		$13.6M Sell
108,382
-1,291
-1% -$148K 0.73% 40
2025
Q1 		$12.1M Sell
109,673
-959
-0.9% -$121K 0.71% 42
2024
Q4 		$15.1M Sell
110,632
-6,785
-6% -$839K 0.83% 34
2024
Q3 		$13.5M Sell
117,417
-688
-0.6% -$94.3K 0.73% 42
2024
Q2 		$16.3M Sell
118,105
-8,316
-7% -$1.14M 0.98% 25
2024
Q1 		$17.4M Sell
126,421
-5,200
-4% -$710K 1% 25
2023
Q4 		$17.3M Sell
131,621
-592
-0.4% -$68.1K 1% 26
2023
Q3 		$14.9M Sell
132,213
-2,857
-2% -$301K 0.94% 31
2023
Q2 		$12.7M Sell
135,070
-2,167
-2% -$212K 0.72% 43
2023
Q1 		$13.9M Sell
137,237
-12,130
-8% -$1.26M 0.79% 36
2022
Q4 		$17.8M Sell
149,367
-3,552
-2% -$416K 1.02% 26
2022
Q3 		$16.2M Sell
152,919
-49,627
-25% -$5.04M 0.94% 29
2022
Q2 		$19.7M Sell
202,546
-4,209
-2% -$388K 0.95% 31
2022
Q1 		$19.4M Buy
206,755
+136,782
+195% +$11.6M 0.77% 39
2021
Q4 		$5.96M Sell
69,973
-8,052
-10% -$741K 0.21% 93
2021
Q3 		$7.48M Sell
78,025
-5,231
-6% -$494K 0.28% 77
2021
Q2 		$8.1M Sell
83,256
-14
-0% -$1.34K 0.29% 74
2021
Q1 		$8.1M Sell
83,270
-3,848
-4% -$404K 0.26% 78
2020
Q4 		$8.35M Buy
87,118
+12,938
+17% +$1.25M 0.29% 73
2020
Q3 		$7.13M Buy
74,180
+9,140
+14% +$1.06M 0.29% 75
2020
Q2 		$7.93M Sell
65,040
-993
-2% -$110K 0.34% 82
2020
Q1 		$5.71M Sell
66,033
-824
-1% -$80.6K 0.32% 92
2019
Q4 		$7.19M Buy
66,857
+5,362
+9% +$561K 0.24% 115
2019
Q3 		$5.54M Sell
61,495
-654
-1% -$61.1K 0.2% 116
2019
Q2 		$5.25M Sell
62,149
-11,575
-16% -$950K 0.17% 126
2019
Q1 		$6.5M Buy
73,724
+29,983
+69% +$2.51M 0.21% 121
2018
Q4 		$3.12M Buy
+43,741
New +$4.19M 0.11% 134

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rice Hall James & Associates's NBIX Position: Q2 2026 in Review

Rice Hall James & Associates increased its Neurocrine Biosciences (NBIX) stake by 0.21% in Q2 2026, buying an estimated $30.4K and bringing the position to 100,195 shares worth $16.9M. The position accounts for 0.82% of the portfolio, ranked #39.

Rice Hall James & Associates first reported a position in NBIX in Q4 2018 and has held it in 31 quarters since. The position peaked at $19.7M in Q2 2022. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Rice Hall James & Associates held 100,195 shares of Neurocrine Biosciences worth $16.9M as of Q2 2026.
  • Rice Hall James & Associates bought 205 Neurocrine Biosciences shares in Q2 2026, an estimated $30.4K.
  • Neurocrine Biosciences made up 0.82% of Rice Hall James & Associates's portfolio in Q2 2026, its #39 holding.
  • Rice Hall James & Associates first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 31 quarters since.
  • Rice Hall James & Associates's Neurocrine Biosciences position peaked at $19.7M in Q2 2022.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.